We serve Chemical Name:6-chloro-2-thiophen-2-ylquinoline-4-carboxylic acid CAS:33289-51-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-chloro-2-thiophen-2-ylquinoline-4-carboxylic acid
CAS.NO:33289-51-9
Synonyms:6-chloro-2-thien-2-ylquinoline-4-carboxylic acid
Molecular Formula:C14H8ClNO2S
Molecular Weight:289.73700
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:486.2ºC at 760 mmHg
Density:1.478g/cm3
Index of Refraction:1.714
PSA:78.43000
Exact Mass:288.99600
LogP:4.31490
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-chloro-2-thien-2-ylquinoline-4-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-chloro-2-thien-2-ylquinoline-4-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-chloro-2-thien-2-ylquinoline-4-carboxylic acid Use and application,6-chloro-2-thien-2-ylquinoline-4-carboxylic acid technical grade,usp/ep/jp grade.
Related News: “We’re going to further invest in research and development to continue to build our pipeline of products, in a more sophisticated way,” he says, holding up a pocket-sized wearable device and a tiny insulin pen to his screen’s camera. “We really believe in this business for the next—we hope—70 years.” Benzenamine, 4-[bis(9-ethyl-9H-carbazol-3-yl)methyl]-N,N-dimethyl- manufacturers “This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. 1-(5-((2,2-dihydroxy-1-oxo-14,24-trioxidaneyl)oxy)-13,24,33,43,54,63-hexaoxin-2-yl)-3-(24-trioxidaneylidene)-16,34,44,51-pentaoxidane-1,1,4-trione suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. 4-(5,6-diethyl-2-methyl-benzofuran-3-yl)-phenol vendor & factory However, to leverage these benefits, it is vital that biocatalytic processes be evaluated as early in the drug development life cycle as possible. Fortunately, the growing availability of diverse kits of enzyme classes can facilitate this process, allowing researchers to screen enzymes/biocatalysts in much the same way as traditional screening of metal catalysts is performed.,“We’re going to further invest in research and development to continue to build our pipeline of products, in a more sophisticated way,” he says, holding up a pocket-sized wearable device and a tiny insulin pen to his screen’s camera. “We really believe in this business for the next—we hope—70 years.”
